CUPID: a protocol of a randomised controlled trial to identify characteristics of similar Chinese patent medicines
Open Access
Abstract
Introduction Traditional Chinese medicine (TCM) has accumulated some experience in curing stable angina pectoris (SAP) and efficacy has been demonstrated. Chinese patent medicines, known as modern dosage forms of TCM, can attain the desired effect in clinical application only with the guidance of TCM syndrome theory. However, due to their use by a large number of persons with little knowledge of TCM theories and practices, their efficacy and reputation have been seriously affected. Method and analysis Two common syndrome types of SAP in TCM, ‘qi deficiency and blood stasis’ and ‘qi stagnation and blood stasis’, will be studied in 144 subjects from four TCM hospitals in Tianjin in China using a partial crossover design. The two syndromes will be broken down into six symptom combinations; patients will select a combination of the most distressing to them, and then will be randomised into two groups. Each group, on the basis of routine medication, will be administered one kind of Chinese patent drug: Qishenyiqi Dripping Pills or Compound Danshen Dripping Pills. The treatment characteristics of the two medicines will be evaluated with the COME-PIO method developed by our research team. Ethics and dissemination This protocol has been approved by the medical ethics committee of Tianjin University of TCM (registration number TJUTCM-EC20130005). The study is safe and reliable. Trial registration number Chinese clinical trials register ChiCTR-TTRCC-14004406.Keywords
This publication has 20 references indexed in Scilit:
- Hand therapist use of patient report outcome (PRO) in practice: A survey studyJournal of Hand Therapy, 2014
- Data-mining of potential antitubercular activities from molecular ingredients of traditional Chinese medicinesPeerJ, 2014
- Comparative Effectiveness Research in Hand SurgeryHand Clinics, 2014
- Minimal Clinically Important Differences in Quality of Life Scores of Oral Cavity and Oropharynx Cancer PatientsAnnals of Surgical Oncology, 2014
- Use of comparative effectiveness research for similar Chinese patent medicine for angina pectoris of coronary heart disease: a new approach based on patient-important outcomesTrials, 2014
- Minimal Clinically Important Difference (MCID)—Adding Meaning to Statistical InferenceAmerican Journal of Public Health, 2013
- Safety and Efficacy of Ranolazine for the Treatment of Chronic Angina PectorisClinical Medicine Insights: Therapeutics, 2013
- Patient-reported outcomes in meta-analyses --Part 2: methods for improving interpretability for decision-makersHealth and Quality of Life Outcomes, 2013
- Traditional Chinese Herbal Products for Coronary Heart Disease: An Overview of Cochrane ReviewsEvidence-Based Complementary and Alternative Medicine, 2012
- Minimal Important Difference (MID) of two commonly used outcome measures for foot problemsJournal of Foot and Ankle Research, 2010